Incannex Healthcare INC 8-K filings

Incannex Healthcare Inc. announced the receipt of a final A$5.1 million R&D tax incentive refund, bringing the total non-dilutive capital received in 2026 to over A$11.2 million, significantly bolstering its financial flexibility.

Incannex Healthcare has commenced participant screening for its DReAMzz Phase 2 study of IHL-42X, a potential treatment for obstructive sleep apnea, marking a significant step towards Phase III development.

Incannex Healthcare has been granted a U.S. patent for its IHL-42X obstructive sleep apnoea treatment, extending intellectual property protection through 2040.

Incannex Healthcare announced the receipt of A$6.0 million in R&D tax incentive refunds, with an additional A$5.1 million expected, bolstering its financial position without dilution.

Incannex Healthcare announces initiation of equity research coverage by Alliance Global Partners with a BUY rating and a US$18.00 price target.

Incannex Healthcare has officially commenced its DReAMzz clinical study for IHL-42X, a potential treatment for obstructive sleep apnea, marking a significant step in its late-stage development.

Incannex Healthcare Inc. has won the MedTech Breakthrough Award for Best New Technology Solution for Drug Development for its obstructive sleep apnea treatment candidate, IHL-42X.

Incannex Healthcare Inc. announces its PSX-001 oral synthetic psilocybin program aligns with a recent White House Executive Order aimed at accelerating access to psychedelic treatments for serious mental illness.

Incannex Healthcare Inc. reactivated its share repurchase program, citing undervaluation and strong financial position.

Incannex Healthcare Inc. announced a partnership with the AASM Foundation and significant progress in its IHL-42X program for obstructive sleep apnea.

Incannex Healthcare Inc. reports a strong balance sheet with approximately $75 million in cash and no debt, while advancing its IHL-42X and PSX-001 clinical programs.

Incannex Healthcare Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Incannex Healthcare Inc. announced the pricing of a $10 million registered direct offering to fund its DReAMzz Phase 2 study and general corporate purposes.

Incannex Healthcare Inc. terminated its sales agreement, having raised $108.4 million, and announced an enhanced Phase 2 dose-optimization study for its lead obstructive sleep apnea drug, IHL-42X, which received FDA Fast Track designation.

Incannex Healthcare Inc. announced a 1-for-30 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Incannex Healthcare Inc. announced the appointment of three new members to its Clinical Advisory Board to bolster expertise for the PSX-001 program.

Incannex Healthcare Inc. announced the formation of a Clinical Advisory Board to guide the PSX-001 development program for generalized anxiety disorder.

Incannex Healthcare Inc. held its 2025 Annual Meeting of Stockholders, electing two directors and ratifying Grant Thornton Audit Pty Ltd as its independent auditor.

Incannex Healthcare Inc. received the 2025 Clinical Trials Arena Excellence Award for its innovative obstructive sleep apnea program, IHL-42X.

Incannex Healthcare Inc. reports significant clinical, regulatory, and financial achievements in 2025, entering 2026 with over $70 million in cash and a clear development pathway.

Incannex Healthcare Inc. adjourned its 2025 annual meeting due to a lack of quorum, stemming from an administrative error that misclassified an auditor ratification proposal.

Incannex Healthcare Inc. announced that its IHL-42X product candidate for obstructive sleep apnea received U.S. FDA Fast Track designation.

Incannex Healthcare Inc. provides a shareholder update detailing positive Phase 2 clinical trial results for IHL-42X and PSX-001, alongside disciplined capital management.

Incannex Healthcare Inc. has received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, extending the deadline to April 20, 2026.

Incannex Healthcare Inc. received a second 180-day period from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, extending the deadline to April 20, 2026.

Incannex Healthcare Inc. announced positive Phase 2 clinical trial results for PSX-001 (Psi-GAD), a psilocybin-assisted therapy for Generalised Anxiety Disorder.

Incannex Healthcare Inc. announced its Board of Directors authorized a share repurchase program for up to $20 million of its common stock.

Incannex Healthcare Inc. reports compelling Phase 2 efficacy and positive patient outcomes for IHL-42X in Obstructive Sleep Apnoea.

Incannex Healthcare Inc. announced a strong cash position of approximately US$50 million and no immediate plans to fully utilize its At-The-Market offering program, while also highlighting better-than-expected Phase 2 results for its drug candidate IHL-42X.

Incannex Healthcare Inc. announced positive topline results from its RePOSA Phase 2 clinical trial for IHL-42X, a novel oral drug candidate for obstructive sleep apnoea, demonstrating significant efficacy and an outstanding safety profile.